Affimer molecules are being developed as multi-specific therapies including antagonists and co-stimulatory agonists, and to target drug conjugates both in-house in Avacta’s proprietary immuno-oncology pipeline and with partners.
Avacta works with therapeutics development partners through research collaborations where there is mutual interest in co-funding a development programme and through fully funded licensing arrangements in which lead Affimer molecules may be transferred to a partner for development.
Current Publicly Disclosed Partnerships
Moderna has exclusive access to Affimer technology against certain targets and is currently evaluating pre-clinical Affimers during its option period to enter into exclusive license agreements for selected therapeutic Affimer candidates.
Avacta has partnered with Glythera, the developer of advanced, stable conjugation chemistries and novel, ultra-potent toxin payloads, to evaluate the use of Glythera’s PermaLink™ conjugation chemistry in combination with Affimer® technology with the aim of developing a new class of highly targeted bio-therapeutics as a superior alternative to the established class of antibody drug conjugates (ADCs).
Avacta and OncoSec, a company developing intratumoral cancer immunotherapies, have entered into a research collaboration to combine the Affimer protein platform with OncoSec's gene delivery technology ImmunoPulse®. The research programme will evaluate the benefits of delivering Affimer protein genes directly into tumors using the OncoSec technology with the long-term aim of developing gene delivered Affimer immunotherapies.
PhoreMost is a Cambridge, UK based drug discovery company aiming to discover new druggable targets and therapies in cancer, and other unmet diseases, using its novel SiteSeeker technology. SiteSeeker can rapidly identify unexpected or hidden drug targets that cannot be found readily by conventional methods. It requires a large library of binding proteins to be introduced into cells to carry out a phenotypic screen. Affimer technology is ideal for this due to its small size, simple structure and lack of disulphide bridges, meaning an Affimer can be easily produced within the cell.
Avacta has agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston. The collaboration will develop a new class of therapies called TMACTM (Tumor Microenvironment Activated Conjugate) which have a dual mode of action combining an immuno-oncology active Affimer with a chemotoxin that is specifically released in the tumour microenvironment.
Memorial Sloan Kettering Cancer Center
Avacta has entered into a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Affimer technology in novel CAR-T cell-based immunotherapy. As part of the collaboration Avacta will develop Affimer molecules that bind different regions of CD19, a surface protein specific to B-cells involved in lymphomas. MSK will construct CAR-T cells incorporating these Affimer molecules and test their anti-tumour function in vitro and in in vivo animal efficacy models.
For further information about working with Avacta to develop Affimer therapeutics please contact us at firstname.lastname@example.org.